Therapeutic Antibodies

Human liver
#Biologics #Liver cancer #Oncology

AstraZeneca’s liver cancer therapy gets accepted for review  

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. Tremelimumab is a human monoclonal antibody which AstraZeneca is investigating as a potential therapy for cancers. It works by targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Now, tremelimumab… Read More

#News

Laboratory research
#Antibodies #Flow Cytometry #Protein targets

Flow cytometry protocols for extracellular & intracellular targets

Flow cytometry is a high throughput quantitative analysis tool that employs fluorescent-labelled molecules for multi-parametric analysis of millions of individual cells or particles. In biomedical sciences, the flow cytometry assays involve a careful selection of antibodies, fluorochrome labels for detection, and often requires optimisation of protocols for an accurate analysis… Read More

#App Notes #Intelligence #News

#Antibodies #Drug delivery

New range of detection reagents for R&D and diagnostic markets 

Jackson ImmunoResearch, manufacturers of secondary antibodies and immunoreagents for the life science market, has announced a new range of detection reagents for improved image quality.  Nano Secondaries   Jackson ImmunoResearch Nano Secondaries are polyclonal VHH Fragment antibodies (Nanobodies*) produced in Alpacas. They are available with specificity… Read More

#News

#Biologics #Drug discovery

With biologic drug discovery mounting, CAS announces expansion 

CAS, a division of the American Chemical Society specialising in scientific information solutions, has launched an expansion of the CAS SciFinder Discovery Platform into life sciences. The enhanced platform includes over two million modified biosequences, 60 years of patent literature, and one of the largest collections of journal information… Read More

#News

#Antibodies #Assays

App Note explains the power of anti-idiotype antibodies

Assessing the safety and efficacy of biotherapeutics is imperative during the drug-development process. In particular, pharmacokinetic (PK) and anti-drug antibody (ADA) assays are conducted to study and evaluate new drug candidates and biosimilars. For PK/ADA assays, anti-idiotype antibodies (Anti-IDs) are powerful tools to measure the concentration of antibody drugs in… Read More

#News #Trending News

#Antibodies #Biotechnology #Collaboration #Neurodegenerative disorders #Neuroscience

Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach.  Background  In November 2017, Ono and Neurimmune signed… Read More

#News

#Antibodies #Autoimmune disease #Clinical trials #Therapeutics

eBook: Antibody production

In immunoassays-based research, immunodiagnostics, as well as immunotherapy, one of the highly critical aspect of antibodies is their reproducible performance. Antibody reproducibility is driven by their specificity and several other factors ranging from antibody design to target validation. This NEW eBook Antibody Production gives you an overview of the… Read More

#News

#Antibodies #Biotherapeutics #Covid variants #Covid-19 #Omicron

Antibody neutralises Omicron and Delta in live virus studies 

Revelar Biotherapeutics and Twist Bioscience have announced that RBT-0813 binds to and neutralises the Omicron and Delta variants of SARS-CoV-2 in live virus studies.   What is RBT-0813?  RBT-0813 is a bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar has continued… Read More

#News #Trending News

#Biologics #Biotechnology #Pharmaceuticals #Research

Sino Biological establishes new location in Texas 

Sino Biological, provider of biological research reagents and related technical contract research services, has expanded to a new location in Houston, Texas.  The company has headquarters in Beijing, China and subsidiaries in Suzhou (China), Taizhou (China), Frankfurt (Germany), and Wayne (Pennsylvania, US). The new location in Houston allows for… Read More

#News

#Antibodies #Clinical trials #HIV #Immunology / Virology & Vaccines #mRNA

Experimental mRNA HIV vaccine is safe and shows promise in animals 

An experimental HIV vaccine based on mRNA shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results The results, published in Nature Medicine, show that the novel vaccine was safe and… Read More

#News

#Antibodies #Immune cells #Immunology

Scientists reveal how the body controls allergy-causing immune cells 

Scientists at the Francis Crick Institute have uncovered biological processes key to regulating immune cells that can cause allergic reactions unless closely controlled, which they hope could help expose what goes wrong when the body develops allergies or goes into anaphylaxis.  Background  IgE antibodies are… Read More

#News

#Antibodies #Covid-19 #Nanobodies #Therapeutics

Can llama antibodies help develop a Covid-19 therapy?

Amid the growing threat of a new and potentially more dangerous SARS-CoV-2 variant, scientists are ramping up the quest for Covid treatments. A recent study demonstrates the therapeutic potential of an unusual class of immune proteins: miniature antibodies called nanobodies, derived from llamas. Rockefeller University scientists Michael P. Rout and Brian T. Chait and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Monoclonal antibodies #Reagents #Research

Sino Biological launches panel of research reagents for Omicron variant

Sino Biological has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus. The new Omicron product line includes recombinant Omicron spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognising the Omicron spike protein, and the Omicron pseudovirus assay CRO service. These… Read More

#News

#Antibodies #Biotechnology #Cancer research #Immunotherapy #Therapeutics

MImAbs acquires antibody discovery system

MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.  The acquisition  This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More

#News

#Antibody #Biologics #Biosciences #Drug discovery

Twist Bioscience acquires Abveris to bolster biopharma capabilities  

Twist Bioscience has acquired Abveris, which will offer Twist comprehensive antibody discovery and characterisation services using its DiversimAb family of hyperimmune mouse models, the output of which can be humanised using the Twist antibody optimisation solution to develop biologics for rapid clinical advancement.   Emily Leproust, CEO and co-founder of Twist Bioscience, believes that the addition of the Abveris discovery… Read More

#News

#Antibodies #Biotherapeutics #Covid-19 #Data #Funding #Immunology / Virology & Vaccines

Twist Bioscience spins out Covid antibodies into Revelar Biotherapeutics

Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.   In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More

#Covid-19 #News